Mineralys Therapeutics (NASDAQ:MLYS) Downgraded to “Strong Sell” Rating by Zacks Research

Zacks Research downgraded shares of Mineralys Therapeutics (NASDAQ:MLYS) from a hold rating to a strong sell rating in a research report report published on Thursday morning,Zacks.com reports.

MLYS has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. TD Cowen began coverage on shares of Mineralys Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating for the company. Jefferies Financial Group reissued a “hold” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Wall Street Zen lowered shares of Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Mineralys Therapeutics presently has a consensus rating of “Hold” and an average price target of $49.33.

Mineralys Therapeutics Stock Down 1.7%

Mineralys Therapeutics stock opened at $25.64 on Thursday. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of -6.05 and a beta of 0.68. Mineralys Therapeutics has a 52 week low of $14.16 and a 52 week high of $47.65. The business’s 50-day moving average price is $26.48 and its 200 day moving average price is $27.54. The company has a quick ratio of 44.33, a current ratio of 34.46 and a debt-to-equity ratio of 0.18.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.30). As a group, sell-side analysts anticipate that Mineralys Therapeutics will post -3.89 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider David Malcom Rodman sold 9,890 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $23.81, for a total value of $235,480.90. Following the completion of the sale, the insider directly owned 57,095 shares in the company, valued at $1,359,431.95. The trade was a 14.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $25.00, for a total value of $75,000.00. Following the transaction, the director directly owned 6,200 shares of the company’s stock, valued at approximately $155,000. The trade was a 32.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 217,313 shares of company stock worth $5,624,488. Company insiders own 18.94% of the company’s stock.

Institutional Investors Weigh In On Mineralys Therapeutics

A number of institutional investors have recently added to or reduced their stakes in MLYS. Man Group plc acquired a new stake in Mineralys Therapeutics in the 2nd quarter valued at $1,609,000. Jupiter Topco LLC acquired a new position in Mineralys Therapeutics during the second quarter worth $773,000. ADAR1 Capital Management LLC acquired a new position in Mineralys Therapeutics during the second quarter worth $8,064,000. Canada Pension Plan Investment Board purchased a new position in Mineralys Therapeutics during the second quarter valued at $1,387,000. Finally, Parkman Healthcare Partners LLC purchased a new position in Mineralys Therapeutics during the second quarter valued at $10,262,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Key Stories Impacting Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Near-term estimates improved: HC Wainwright raised its Q3 2026 EPS estimate to a loss of $0.56 from $0.61 and its Q4 estimate to a loss of $0.60 from $0.70. The firm maintained its Buy rating, indicating continued confidence in Mineralys’ prospects. Mineralys Therapeutics analyst coverage
• Positive Sentiment: Regulatory catalyst remains intact: Mineralys reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational hypertension treatment, and said launch preparations are advancing. Approval could provide the company with its first commercial opportunity. Mineralys second-quarter results and corporate update
• Positive Sentiment: Cash runway and leadership support the launch plan: Management said its funding should support operations into 2028, while the appointment of Dr. Terry Ferguson as chief medical officer adds cardiovascular-development expertise ahead of a potential launch.
• Neutral Sentiment: Inducement awards granted to new CMO: Mineralys authorized options covering 135,000 shares and restricted stock units covering 102,400 shares for Dr. Ferguson. The awards help recruit key leadership but could modestly increase future share dilution. Mineralys inducement award announcement
• Negative Sentiment: Large quarterly earnings miss: Mineralys reported a second-quarter loss of $2.85 per share, far worse than the $0.55 consensus loss. The result highlights ongoing pre-commercial cash burn and likely contributes to investor caution.
• Negative Sentiment: Long-term earnings outlook was reduced: HC Wainwright cut its FY2026 EPS forecast to a loss of $4.47 from $2.33, FY2027 to a loss of $3.78 from $2.84, and FY2028 to a loss of $2.27 from $1.52. Its FY2029 profit estimate fell to $0.42 from $0.92, while FY2030 declined to $3.41 from $3.73. These revisions suggest profitability may take longer to develop.
• Negative Sentiment: Insider selling adds a modest negative signal: David Malcom Rodman sold 2,170 shares for approximately $58,785, reducing his stake by 4.05%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which limits its signaling value. Mineralys insider sale

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.